Rivaroxaban frente a heparinas de bajo peso molecular para la prevención de la tromboembolia venosa posterior al reemplazo total de cadera o rodilla: Revisión sistemática de la literatura y metaanálisisis

Natalia Aristizábal Henao, Juan Pablo Montoya Lopera, Jorge Hernando Donado Gómez

    Resultado de la investigación: Contribución a una revistaArtículorevisión exhaustiva

    Resumen

    Objective: To assess the efficacy and safety of rivaroxaban thromboprophylaxis versus low weight heparins in major hip and knee arthroplasty. Methods: Systematic review in Central Cochrane Database, MEDLINE, EMBASE, LILACS, CINAHL, and referenced articles. Only randomized clinical trials were considered. The search was made until October 31, 2011. Two independent reviewers assessed the quality of articles and extracted the information. Results: 15.638 patients who underwent major orthopedic surgery were studied (nine trials). Compared with enoxaparin, thromboprophylaxis with rivaroxaban was associated with lower incidence of deep vein thrombosis, pulmonary embolism and death from any cause after major hip surgery (5.351, relative risk [RR]: 0.37; confidence interval 95% [IC 95%]: 0.29-0.48) and knee surgery (2.878, RR: 0.65; IC 95%: 0.50-0.84) without differences in bleeding events (major bleeding events in hip surgery: 7.684, RR: 1.79; IC 95%: 0.78-4.11) and knee surgery: 5.700, RR: 1.59; IC 95%: 0.77-3.27). Conclusion: Rivaroxaban thromboprophylaxis in major hip and knee arthroplasty is more effective than enoxaparin and as safe as the latter.

    Título traducido de la contribuciónRivaroxaban versus low weight heparins for venous thromboembolism prophylaxis after major hip and knee arthroplasty: Systematic review and metaanalysis
    Idioma originalEspañol
    Páginas (desde-hasta)136-152
    Número de páginas17
    PublicaciónIatreia
    Volumen26
    N.º2
    EstadoPublicada - 2013

    Palabras clave

    • Enoxaparin
    • Orthopedics
    • Rivaroxaban
    • Venous thromboembolism

    Huella

    Profundice en los temas de investigación de 'Rivaroxaban frente a heparinas de bajo peso molecular para la prevención de la tromboembolia venosa posterior al reemplazo total de cadera o rodilla: Revisión sistemática de la literatura y metaanálisisis'. En conjunto forman una huella única.

    Citar esto